Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | BRD2 | P25440 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6362566 | 0.83 | BRD4 (0.43) | BRD4BRD2PIK3CDPOLBKMT2A | |
| SCHEMBL13607427 | 0.82 | DRD2 (0.47) | BRD4BRD2PIK3CDPOLBNPC1 | |
| SCHEMBL771636 | 0.81 | BRD4 (0.46) | BRD4BRD2PIK3CDPOLBNPC1 | |
| SCHEMBL13178389 | 0.80 | GNAI3 (0.52) | BRD4BRD2PIK3CDPOLB | |
| SCHEMBL1156274 | 0.80 | PIK3CD (0.62) | BRD4BRD2PIK3CDKMT2AMEN1 | |
| SCHEMBL4661375 | 0.79 | BRD4 (0.55) | BRD4BRD2PIK3CDPOLBKMT2A | |
| SCHEMBL16215111 | 0.78 | POLB (0.46) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL23133704 | 0.78 | BRD4 (0.43) | BRD4BRD2PIK3CDPOLBKMT2A | |
| SCHEMBL25664018 | 0.78 | PIK3CD (0.70) | BRD4BRD2PIK3CDKMT2AMEN1 | |
| SCHEMBL15697002 | 0.76 | BRD4 (0.42) | BRD4BRD2PIK3CDPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208021-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180201603-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208021-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | TFPI, TFPI2, KLKB1 | BRD4 1380/4885BRD2 3166/4885PIK3CD 1552/4885 |
| US-20180201603-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | BRD4 1380/4885BRD2 3166/4885PIK3CD 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.